Marisa Wexler, MS,  senior science writer—

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

CF Foundation Invests in SalioGen’s Gene Coding Therapy

The Cystic Fibrosis Foundation has announced an investment in SalioGen Therapeutics to support the company’s preclinical research toward  developing a new gene therapy for cystic fibrosis (CF). SalioGen is working to advance a novel type of gene therapy, called Gene Coding, which is accomplished using the company’s…

COVID-19 Treatments Opening to High-risk Patients in UK via NHS

People in the U.K. at highest risk of becoming seriously ill from COVID-19 — including those with cystic fibrosis (CF) — starting on Dec. 16 will have access to medications that can lessen the risk of severe disease through the country’s National Health Service (NHS). Two medications will be available:…

Self-compassion Tied to Better Quality of Life in Adults With CF

People with cystic fibrosis (CF) who score highly on measures of self-compassion tend also to report higher quality of life, a study found. “The current findings suggest that psychological interventions which increase self-compassion could be beneficial for enhancing better mental health and quality of life for adults with CF,”…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.